Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : Veristat
Deal Size : Undisclosed
Deal Type : Partnership
Cook MyoSite and Veristat Partner in Phase III, Adaptive Clinical Study of iltamiocel
Details : The partnership aims to support the DigniFI Study, a two-stage, randomized, controlled Phase 3 comparing the safety and efficacy of iltamiocel with placebo.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 16, 2025
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : Veristat
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tacrolimus
Therapeutic Area : Urology
Study Phase : Phase II
Sponsor : Lipella Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
Details : The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 17, 2023
Lead Product(s) : Tacrolimus
Therapeutic Area : Urology
Highest Development Status : Phase II
Sponsor : Lipella Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
Details : Iltamiocel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fecal Incontinence.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Muscle Derived Cell
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program for Autologous Muscle Derived Cells (AMDCs)
Details : Autologous Muscle Derived Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 10, 2020
Lead Product(s) : Autologous Muscle Derived Cell
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable